ConductScience.org, home

Comparison · NCT00935818-0d512b91

Varenicline and Buproprion SR vs Varenicline and Placebo: Point Prevalence Abstinence at 6 Months.

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Varenicline and Buproprion SR vs Varenicline and Placebo: Point Prevalence Abstinence at 6 Months. Trial comparisons, record NCT00935818-0d512b91. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00935818-0d512b91

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.3820.3230.443wilson
Risk in group 20.3190.2650.378wilson
Risk difference, group 1 minus group 20.0625-0.02060.144newcombe hybrid score
Risk ratio, group 1 over group 21.20.9421.52log
Odds ratio, group 1 over group 21.320.9131.9log
Number needed to treat, for one more participant with the outcome on Varenicline and Buproprion SR than on Varenicline and Placebo16from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Varenicline and Buproprion SR
Everyone randomized to this arm will receive varenicline (up to 1mg bid) and bupropion SR (150 mg bid)for 12 weeks. They will be followed up by study for an additional 9 months post end of medication - for a total of 1 year study participation. Everyone will receive behavioral counseling for the full year.~varenicline and bupropion: varenicline - 1 mg bid for 12 weeks bupropion sr - 150 mg bid for 12 weeks
95249OG000
Group 2Varenicline and Placebo
Everyone randomized to this arm will receive varenicline (up to 1mg bid) and placebo (0 mg bid)for 12 weeks. They will be followed up by study for an additional 9 months post end of medication - for a total of 1 year study participation. Everyone will receive behavioral counseling for the full year.~varenicline and placebo: varenicline (1 mg bid) for 12 weeks placebo for 12 weeks
82257OG001

Outcome

Type
SECONDARY
Title
Point Prevalence Abstinence at 6 Months.
Description
Biochemically confirmed abstinence as no smoking, even a puff, for the prior 7 days.
Time frame
6 months
Population
Intention to treat - all subjects

Source ClinicalTrials.gov

Trial

Title
Varenicline and Bupropion for Smoking Cessation
NCT number
NCT00935818
Phases
PHASE2, PHASE3
Conditions
Smoking
Interventions
Varenicline, placebo, bupropion SR
Lead sponsor
Mayo Clinic
Results first posted
2014-04-24

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00935818-0d512b91